Bacterial susceptibility is categorized as susceptible, intermediate-susceptible dose-dependent (ISDD), and resistant. The strategy is to use higher doses of first-line agents in the ISDD category, thereby preserving the use of these drugs. This system has not been applied to antituberculosis drugs. Pharmacokinetic/pharmacodynamic (PK/PD) target exposures, in tandem with Monte Carlo experiments, recently identified susceptibility breakpoints of 0.0312 mg/L for isoniazid, 0.0625 mg/L for rifampin, and 50 mg/L for pyrazinamide. These have been confirmed in clinical studies.

中文翻译：

---

在多药耐药结核病项目中大剂量利福平，异烟肼和吡嗪酰胺治疗的中等药敏剂量依赖性断点

细菌易感性分为易感性，中度易感剂量依赖性（ISDD）和耐药性。该策略是在ISDD类别中使用更高剂量的一线药物，从而保留这些药物的使用。该系统尚未应用于抗结核药物。药代动力学/药效学（PK / PD）目标暴露与蒙特卡洛实验相结合，最近确定了异烟肼的敏感性折点为0.0312 mg / L，利福平为0.0625 mg / L，吡嗪酰胺为50 mg / L。这些已经在临床研究中得到证实。